The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Premier African Minerals Limited
Funding of Zulu Project and Update
The Board of Premier African Minerals Limited ("Premier" or the "Company") is pleased to announce a subscription today to raise £2,475,000 on before expenses at an issue price of 0.275 pence per new ordinary share for the Zulu Lithium and Tantalum Project ("Zulu").
Highlights:
Ø
Premier now funded until first production at Zulu.
Ø
Ball Mill Power on and test run in situ.
Ø
Commencement of Commercial Production in late February with first shipments expected in March 2024.
Ø
Thickener Plant completion date 19 February 2024.
Ø
Ongoing negotiations with Zimbabwe based lenders for working capital facilities at Zulu once in production are progressing.
George Roach, CEO, commented, "This placement assures Zulu of plant startup, subject only to suppliers meeting their obligations and undertakings. This has and remains Premier single most important objective at this stage. That is targeted for next week and remains on target at this time. Early indications are that subsequent working capital finance will be available from commercial lenders at Zulu when production is underway as Zulu must begin to fund its operations without the assistance of Premier once commercial production has commenced.
Helium discovery in Tanzania: Helium One Global discovered a 4.7% helium concentration in the Rukwa Rift Basin, marking a significant breakthrough. This concentration is nearly 9,000 times above background levels.
➡️ Economic potential:
This discovery could position Tanzania as a major helium supplier, joining the few countries currently dominating the market. Helium is crucial for various applications, including medical equipment, electronics, and space exploration.
➡️ Helium One Global holds prospecting licences totalling more than 2,965 Kilometres Square across three distinct project areas which are Rukwa, Balangida, and Eyasi located within rift basins in the north and south-west of Tanzania.
➡️ The Company’s flagship Rukwa Project is located within the Rukwa Rift Basin covering 1,900 kilometre square in the south-west.
➡️ Today, helium is pro- duced primarily in just four countries including in the United States of America (USA), Qatar, Algeria and Russia, whereby limited number of suppliers result into an increase in demand and its price worldwide.
➡️ According to the African Union report, the continent has 30 per cent of the world’s mineral reserves with 91 per cent of platinum and hence it is up to all countries to harness the resource for the continent’s socioeco nomic transformation.
➡️ Government support:
The Tanzanian government is committed to supporting exploration for critical minerals like helium, which aligns with their clean energy transition goals.
➡️ Investment opportunities:
The discovery opens investment opportunities for establishing processing facilities and manufacturing industries using helium in Tanzania.
Key points:
🟢 This discovery could significantly impact the global helium market.
🟢 Tanzania has the potential to become a major helium supplier.
🟢 Further exploration and development are needed to assess the full potential of the reserves.
🟢 The government and private sector are collaborating to exploit this resource responsibly.
It's going to be a very interesting week ahead of us. Buckle up, it's going to be a wild ride!
The detection of elevated helium levels, over 20 times background, throughout the targeted formations in the Itumbula West-1 well is indeed a very promising sign for Helium One Global Ltd. Here are some additional thoughts and insights on this key point:
Significance:
✅Helium is a crucial resource with diverse applications in medical imaging, fiber optic cables, and scientific research. Its scarcity and increasing demand make discoveries like this potentially valuable.
✅Finding helium across multiple formations increases the overall potential resource size and complexity.
✅The magnitude of the helium levels, more than 20 times background, is noteworthy and suggests a potentially significant helium accumulation.
Possible explanations:
✅The presence of fault zones and increased temperature suggests deep-seated helium sources migrating towards the surface.
✅The helium might be originating from various geological processes, such as radioactive decay in the underlying basement rocks or migration from ancient helium-rich sediments.
Implications:
✅The discovery necessitates further investigation through wireline logging and well testing to understand the full extent and quality of the helium resource.
✅Successful confirmation of a viable helium resource could have a significant impact on Helium One's future and potentially spark further exploration in the region.
✅The presence of other elements like hydrogen adds another layer of complexity and potential resource diversification.
I'm looking the US PRE-Market trades 😂
Small peanut trades. Don't fall for the trolls' tactics.
Pre-Market Time (ET) Pre-Market Price Pre-Market Share Volume
05:17:18 $1.15 9
05:17:07 $1.15 100
05:16:42 $1.17 100
05:16:20 $1.15 24
05:14:51 $1.15 5
🟢 Patent Allowance: The US Patent Office has granted a new patent surrounding the biomarkers sTNFR1 and sTNFR2, which are core components of Renalytix's KidneyIntelX.dkd test.
🟢 KidneyIntelX.dkd Background: This is an artificial intelligence-driven blood test that assesses the risk of declining kidney function in patients with type 2 diabetes and early-stage chronic kidney disease. It was authorized by the FDA in June 2023.
Why This Matters
🟢 Strengthens Intellectual Property: The patent reinforces Renalytix's ownership of the core technology behind its KidneyIntelX test.
🟢 Competitive Advantage: The patent, along with other factors like FDA authorization and insurance coverage, positions Renalytix strongly in the market for kidney disease management.
🟢 Barriers to Entry: The strong intellectual property position could make it more difficult for competitors to enter the market with similar solutions.
🟢 Focus on Innovation: The announcement emphasizes Renalytix's commitment to research and development in the field of kidney disease diagnosis.
🟢 European Expansion: Renalytix is pursuing a similar intellectual property strategy in Europe, aiming to expand the reach of KidneyIntelX.
In short, this patent allowance is a significant development for Renalytix, adding protection to its technology and potentially improving its market position.
Renalytix plc (NASDAQ: RNLX) (LSE: RENX), the first company to commercialize an FDA authorized artificial intelligence (AI) enabled blood test to assess risk of progressive kidney function decline for individuals with type 2 diabetes and early-stage chronic kidney disease, announces that the US Patent Office has issued a new notice of allowance of claims surrounding the biomarkers sTNFR1 and sTNFR2 used in the kidneyintelX.dkd test. These claims were filed under US Patent Application No. 16/671.256 by the Joslin Diabetes Center and this patent is exclusively licensed to Renalytix. KidneyintelX.dkd received Food and Drug Administration de Novo marketing authorization on June 29, 2023.
The newly allowed claims further strengthen the core intellectual property underpinning the KidneyIntelX technology by directly incorporating sTNFR1 and sTNFR2 into a set of consolidated claims directed towards identifying risk of early kidney function decline, thereby enabling therapeutic strategies for those at increased risk of progressive decline.
The Company believes this development reflects the Renalytix strategy of innovation in biomarker research, development and translation in collaboration with the Joslin Diabetes Center and other leading research partners globally. When taken together with other key milestones, such as FDA De Novo marketing authorization, broad insurance coverage and published clinical utility and outcomes data, Renalytix believes this increases its competitive advantage. The Company also believes this creates further barriers to entry in the large addressable market for optimizing clinical management of kidney disease to drive improved patient outcomes. A similar strategy to protect Renalytix’s intellectual property is being pursued in Europe, which also presents a large opportunity for KidneyIntelX expansion.
Why this matters:
The conference provides Renalytix with an opportunity to connect with potential investors and raise awareness about their work in kidney health diagnostics.
This type of exposure can be important for companies in the medical technology and diagnostics field.
Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic
Tools Conference
LONDON and SALT LAKE CITY, February 9, 2024 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that the Company will be participating in the upcoming BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which will take place February 13-14, 2024 in Snowbird, Utah. Given the format of this event, no formal company presentation is expected. Management will be participating in one-on-one meetings with investors during the event and meetings can be requested through BTIG.
Sentiment and momentum will dictate SP movements. If you look at yesterday's price action, you'll see that no one on the LSE board posted anything up until in the afternoon. There was a 60% rise in the morning and then a 220% increase at close in the UK.
The US market will react to UK SP action this afternoon.
Let's wait and see.